TNF and rheumatoid arthritis: Notably, even in the field of TNF-targeting therapeutics, where the treatment of rheumatoid arthritis (RA) has been revolutionized by the use of anti-TNF biologics, such as etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab, which have been considered among the most transformative drugs of the 1985–2010 period (26), there is increasing interest in SMIs.